Organisation paid for research Program year 2025 Source: CMS Open Payments

Avance Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$355,406

346 payments

Through program year 2025, Avance Clinical Trials is reported as receiving $355,406 in research payments, across 346 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$144,661	180
2024	Research	$138,031	149
2023	Research	$69,306	15
2022	Research	$2,406	1
2021	Research	$1,003	1

Breakdown

Who paid Research payments · program years 2021–2025

Incyte Corporation $301,905 339 payments
Amgen Inc. $53,501 7 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $142,414 133 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $53,499 85 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa $35,922 74 payments
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $29,953 13 payments
ASTRO P3 AD Adolescent Mono $25,061 2 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa $22,032 27 payments
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib $18,085 7 payments
Ph3 Otezla in Peds mild/mod PsO PMR $17,830 2 payments
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis $7,202 1 payment
Ph2b_chronic urticaria $2,406 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.